Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL
Venetoclax-based treatment was associated with poorer outcomes CLL previously treated with a BTK inhibitor and naive to chemotherapy.
Related Articles
Top 10 Findings Shaping the Future of Breast Cancer Care From SABCS 2024
SABCS 2024 saw a variety of potentially practice-changing findings on novel antibody drug conjugates, biomarker data, and surgical interventions.
Adenoma Detection Rates by Physicians and Subsequent Colorectal Cancer Risk
This observational study investigates the association of adenoma detection rates among physicians who perform colonoscopy and postcolonoscopy colorectal cancer incidence.
Long-Term Adverse Effects and Complications After Prostate Cancer Treatment
This cohort study assesses the long-term adverse effects and complications of prostate cancer treatment in treated patients compared with a general population of older males.
Stay up to date on the latest in Hematology – Hematology.org
Stay up to date on the latest in Hematology
AACR Special Conference in Cancer Research: DNA Methylation, Clonal Hematopoiesis, and Cancer
Overview for AACR Special Conference in Cancer Research: DNA Methylation, Clonal Hematopoiesis, and Cancer
Innovation by collaboration – Outlook Magazine
Brain tumors are among the most challenging cancers to effectively treat. Depending on the tumor’s location, surgery can interfere with cognitive function, movement or language,…
BSA approves four new, five reissue concepts – The Cancer Letter
The NCI Board of Scientific Advisors approved four new concepts and five reissue concepts at a joint meeting of the BSA and the National Cancer…
FDA approves remestemcel-L-rknd for steroid-refractory acute graft ver
On December 18, 2024, the Food and Drug Administration approved remestemcel-L-rknd (Ryoncil, Mesoblast, Inc.), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory…
Moving the Needle in ER-Positive / HER2-Negative MBC
Join us for this social media event on treating estrogen receptor (ER)-positive / HER2-negative metastatic breast cancer designed to encourage the exchange o…
Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant
The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous…
